Qiagen, Lilly Ink CDx Development Pact Targeting Multiple DNA, RNA Markers | GenomeWeb

This article has been updated from a previous version as Qiagen clarified an earlier statement regarding its acquisition of PrimeraDx.

NEW YORK (GenomeWeb) — Qiagen said today that it is collaborating with Eli Lilly to co-develop universal and modular assay panels to simultaneously analyze DNA and RNA biomarkers targeting multiple cellular pathways in common cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.